Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesGenetic & Molecular TestingVentura County Carrier Screening Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentVentura County Health Care PlanPolicy 063

    Universal Carrier Screening Testing Specific to Parents

    Customize your policy alerts

    Sign up for venturacountyhealthcareplan Policy 063 alerts

    Get alerted when Policy 063 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of genetic carrier screening for members who are pregnant or considering pregnancy, including clinical indications, follow-up counseling, testing approaches, and covered coding for cystic fibrosis, fragile X syndrome, hemoglobinopathies, spinal muscular atrophy, and Tay-Sachs disease.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyUniversal Carrier Screening Testing Specific to Parents
    Policy CodePolicy 063
    Change TypeNo material change
    Effective DateMay 8, 2025
    Last ReviewFeb 12, 2026
    Next Review DateN/A
    Key ActionDocument pregnancy or pregnancy-planning status and the clinical indication supporting carrier screening.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    5Condition categories addressed
    5/8/2025

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Effective date
    2/12/2026Latest review
    All pregnant or pregnancy-planning womenSMA screening population
    5Covered coding sections

    Carrier Screening Coverage Criteria

    Cystic Fibrosis Carrier Screening

    Covered when the applicable risk-based indication is met:

    CF indication

    • The woman is considering pregnancy or is pregnant.
    • ONE of

      • Both partners are unaffected, and one or both partners has a family history of cystic fibrosis.

        Genetic counseling and medical-record review should determine whether CFTR mutation analysis from an affected family member is available.

      • The woman's reproductive partner has cystic fibrosis or apparently isolated congenital bilateral absence of the vas deferens.

        Follow-up genetic counseling should be provided by an obstetrician-gynecologist or another healthcare provider with expertise in genetics.

    Fragile X Syndrome

    Covered when the applicable risk-based indication is met:

    Fragile X indication

    • The woman is considering pregnancy or is pregnant.
    • ONE of

      • She has a family history of fragile X-related disorders or intellectual disability suggestive of fragile X syndrome.
      • She has unexplained ovarian insufficiency or failure.
      • She has an elevated follicle-stimulating hormone level before age 40 years.

    Hemoglobinopathies

    Covered when one or more of the following indications is present:

    ONE of

    • The woman is currently pregnant.
    • The woman is being evaluated before pregnancy.
    • Red blood cell indices show a low mean corpuscular hemoglobin or mean corpuscular volume.

      Obtain a complete blood count with red blood cell indices; add hemoglobin electrophoresis when indicated.

    • Hemoglobinopathy is suspected based on African, Mediterranean, Middle Eastern, Southeast Asian, or West Indian descent.

      Perform hemoglobin electrophoresis in addition to a complete blood count.

    Spinal Muscular Atrophy

    Covered when the following criterion is met:

    SMA indication: The member is a woman considering pregnancy or is pregnant.

    Offer screening regardless of race or ethnicity. When there is a family history, review molecular testing reports of the affected individual and carrier testing of the related parent when possible.

    Tay-Sachs Disease

    Covered when the applicable family-history or ancestry indication is met:

    ONE of

    • The member has a family history consistent with Tay-Sachs disease.
    • ALL of the following

      • The woman is considering pregnancy or is pregnant.
      • Either member of the couple is of Ashkenazi Jewish, French Canadian, or Cajun descent.

    Routine cystic fibrosis carrier screening is not advisable when there is no relevant family history. Coverage applies when the woman is considering pregnancy or is pregnant and the couple has a cystic fibrosis family history, or when the reproductive partner has cystic fibrosis or apparently isolated congenital bilateral absence of the vas deferens.

    Covered Screening Indications

    Cystic Fibrosis Carrier Screening

    CFTR mutation analysis is covered when all of the following are met:

    ALL of the following

    • The woman is considering pregnancy or is pregnant.
    • ONE of

      • Both partners are unaffected, and one or both partners has a family history of cystic fibrosis.

        Perform genetic counseling and medical-record review to determine whether mutation analysis from an affected family member is available.

      • The woman's reproductive partner has cystic fibrosis or apparently isolated congenital bilateral absence of the vas deferens.

        Provide follow-up genetic counseling by an obstetrician-gynecologist or another healthcare provider with expertise in genetics.

    Eligibility and Review Requirements

    For a woman considering pregnancy or who is pregnant, cystic fibrosis carrier screening may be considered when one or both unaffected partners have a family history of cystic fibrosis. The record should document the relevant family history, and genetic counseling and medical-record review are required before or during testing to assess the familial risk and determine the appropriate CFTR analysis.

    When cystic fibrosis is reported in the family, review whether CFTR mutation analysis from an affected family member is available before or during offering carrier testing. This information can help guide mutation analysis and genetic counseling for the couple.

    Documentation and Follow-Up Actions

    Documentation Required

    Cystic Fibrosis Indication Documentation

    Document the pregnancy-related indication and relevant family or clinical history before offering cystic fibrosis carrier screening. For family-history cases, obtain genetic counseling and review medical records to determine whether CFTR mutation analysis from an affected relative is available.

    • Woman is considering pregnancy or is currently pregnant.
    • One or both unaffected partners have a family history of cystic fibrosis.
    • Document whether CFTR mutation analysis from the affected family member is available and offer CFTR gene analysis when appropriate.
    Documentation Required

    Fragile X Indication Documentation

    Document the indication for Fragile X premutation carrier screening, including pregnancy status, family history, or relevant ovarian and laboratory findings. Screening is recommended for women considering pregnancy or currently pregnant when the specified risk factors are present.

    • Family history of a fragile X-related disorder or intellectual disability suggestive of fragile X syndrome.

    Covered Procedure Codes

    Cystic Fibrosis Carrier ScreeningCPTCovered
    81220CFTR Common Mutation Panel
    Fragile X Syndrome Carrier ScreeningCPTCovered
    81243FMR1 Repeat Analysis
    81244FMR1 Repeat Analysis
    HemoglobinopathiesCPTCovered
    81257hemoglobin electrophoresis or HPLC, CBC, Blood smear
    81259hemoglobin electrophoresis or HPLC, CBC, Blood smear
    81361hemoglobin electrophoresis or HPLC, CBC, Blood smear
    83020hemoglobin electrophoresis or HPLC, CBC, Blood smear
    Sickle Cell Disease-ThalassemiaCPTCovered
    81257hemoglobin electrophoresis or high-performance liquid chromatography (HPLC)
    81259hemoglobin electrophoresis or high-performance liquid chromatography (HPLC)
    81361hemoglobin electrophoresis or high-performance liquid chromatography (HPLC)
    Spinal Muscular Atrophy Carrier ScreeningCPTCovered
    81329SMN1 Deletion/Duplication Analysis
    81336SMN1 Deletion/Duplication Analysis
    81337SMN1 Deletion/Duplication Analysis
    Spinal Muscular Atrophy Carrier Screening — SMN2 Deletion/Duplication AnalysisCPTCovered
    No codes listed
    Tay-Sachs DiseaseCPTCovered
    81255enzyme analysis and gene sequencing
    81443enzyme analysis and gene sequencing
    81406enzyme analysis and gene sequencing

    Policy Background

    Carrier screening evaluates prospective or current parents for pathogenic genetic variants that may cause inherited disorders in their children. Carriers generally do not have the disorder themselves, but when both parents carry relevant variants, the risk of an affected child may be increased. Testing may use blood, saliva, or cheek-swab specimens and can support reproductive counseling and family-planning decisions.

    Key Definitions

    Carrier
    DefinitionAn individual who usually is not at risk of developing the inherited disorder but may pass a pathogenic variant to a child.
    Prenatal Genetic Carrier Screening
    DefinitionA blood test that screens for genetic variations (mutations) in parents that could potentially lead to inherited disorders in their children. Saliva or cheek swabs can also be used.

    Non-Advisable Screening

    Routine cystic fibrosis carrier screening in the absence of a family history is not advisable under this policy. For couples with a cystic fibrosis family history, genetic counseling and medical-record review should first determine whether mutation analysis from an affected family member is available.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyUniversal Carrier Screening Testing Specific to Parents
    Policy CodePolicy 063
    Change TypeNo material change
    Effective DateMay 8, 2025
    Last ReviewFeb 12, 2026
    Next Review DateN/A
    Key ActionDocument pregnancy or pregnancy-planning status and the clinical indication supporting carrier screening.
    SourceLink
    On This Page
    Carrier Screening Coverage CriteriaCovered Screening IndicationsEligibility and Review RequirementsDocumentation and Follow-Up ActionsCovered Procedure CodesPolicy BackgroundKey DefinitionsNon-Advisable Screening

    Fragile X Premutation Screening

    Fragile X premutation screening is covered when all of the following are met:

    ALL of the following

    • The woman is considering pregnancy or is pregnant.
    • ONE of

      • She has a family history of fragile X-related disorders or intellectual disability suggestive of fragile X syndrome.
      • She has unexplained ovarian insufficiency or failure.
      • She has an elevated follicle-stimulating hormone level before age 40 years.

    Hemoglobinopathy Evaluation

    Hemoglobinopathy evaluation is covered when one or more of the following indications is present:

    ONE of

    • The woman is currently pregnant.
    • The woman is being evaluated before pregnancy.
    • Red blood cell indices show a low mean corpuscular hemoglobin or mean corpuscular volume.

      Obtain a complete blood count with red blood cell indices before adding hemoglobin electrophoresis.

    • Hemoglobinopathy is suspected based on African, Mediterranean, Middle Eastern, Southeast Asian, or West Indian descent.

      Perform hemoglobin electrophoresis in addition to a complete blood count.

    Spinal Muscular Atrophy Carrier Screening

    Covered when the following criterion is met:

    The member is a woman considering pregnancy or is pregnant.

    Offer screening regardless of race or ethnicity. For a family history of spinal muscular atrophy, review molecular testing reports of the affected individual and carrier testing of the related parent when possible; if unavailable, recommend SMN1 deletion testing for the low-risk partner.

    Tay-Sachs Screening

    Tay-Sachs screening is covered when one of the following indications is present:

    ONE of

    • The member has a family history consistent with Tay-Sachs disease.
    • ALL of the following

      • The woman is considering pregnancy or is pregnant.
      • Either member of the couple is of Ashkenazi Jewish, French Canadian, or Cajun descent.
  1. Unexplained ovarian insufficiency or ovarian failure.
  2. Elevated follicle-stimulating hormone level before age 40 years.
  3. Record pregnancy or pregnancy-planning status and the relevant clinical findings.
  4. Documentation Required

    Hemoglobinopathy Indication Documentation

    Document pregnancy or preconception status and the findings supporting hemoglobinopathy evaluation. Complete blood count with red blood cell indices is indicated, with additional testing based on indices or ethnicity-related suspicion.

    • Currently pregnant or ideally evaluating before pregnancy.
    • CBC with red blood cell indices, including mean corpuscular hemoglobin and mean corpuscular volume.
    • Hemoglobin electrophoresis when indices show low mean corpuscular hemoglobin or mean corpuscular volume.
    • Hemoglobin electrophoresis in addition to CBC when there is suspicion based on African, Mediterranean, Middle Eastern, Southeast Asian, or West Indian ancestry.
    Documentation Required

    SMA Indication Documentation

    Document that the woman is considering pregnancy or is currently pregnant before offering spinal muscular atrophy carrier screening. When there is a family history, review available molecular testing reports before testing whenever possible.

    • Pregnancy or pregnancy-planning status.
    • Family history of spinal muscular atrophy, if applicable.
    • Molecular testing report for the affected individual and carrier testing report for the related parent, if available.
    • If reports are unavailable, recommend SMN1 deletion testing for the low-risk partner.
    Documentation Required

    Tay-Sachs Indication Documentation

    Document the Tay-Sachs screening indication, including pregnancy or pregnancy-planning status and the relevant family history or ancestry. Screening should be offered when either member of the couple has qualifying ancestry or when there is a family history consistent with Tay-Sachs disease.

    • Woman is considering pregnancy or is currently pregnant.
    • Family history consistent with Tay-Sachs disease.
    • Ashkenazi Jewish, French Canadian, or Cajun ancestry in either member of the couple.

    Unsupported block type: denial_risk

    Denial Risk

    Tay-Sachs Screening Indication Required

    Do not submit Tay-Sachs screening without documenting a qualifying indication. The record should establish pregnancy or pregnancy-planning status plus either relevant family history or Ashkenazi Jewish, French Canadian, or Cajun ancestry in either partner.

    • Screening is offered to women considering pregnancy or currently pregnant.
    • Document family history consistent with Tay-Sachs disease, or qualifying ancestry in either member of the couple.
    • Qualifying ancestry includes Ashkenazi Jewish, French Canadian, or Cajun descent.
    Documentation Required

    Provider Action: CF Family-History Review

    For couples in which both partners are unaffected but one or both has a family history of cystic fibrosis, perform genetic counseling and medical-record review before testing. Determine whether CFTR mutation analysis in the affected family member is available and document the testing rationale.

    • Review records from the affected family member, when available.
    • Use the family member's mutation analysis to guide CFTR testing of the couple.
    • Document counseling and the outcome of the medical-record review.
    Documentation Required

    Provider Action: CF Follow-Up Counseling

    If a woman's reproductive partner has cystic fibrosis or apparently isolated congenital bilateral absence of the vas deferens, arrange follow-up genetic counseling with an obstetrician-gynecologist or another qualified genetics provider. Counseling should address mutation analysis and consultation regarding reproductive risk.

    • Identify whether the reproductive partner has cystic fibrosis or apparently isolated congenital bilateral absence of the vas deferens.
    • Refer for follow-up counseling by an obstetrician-gynecologist or health care provider with expertise in genetics.
    • Document the recommendation for mutation analysis and genetics consultation.